Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.
Stahl SM.
CNS Spectr · journal article · DOI 10.1017/s1092852916000407 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för pimavanserin. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
24 hitsPimavanserin: First Global Approval.
Markham A.
Drugs · review; journal article · DOI 10.1007/s40265-016-0597-9The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease.
Hermanowicz S, Hermanowicz N.
Expert Rev Neurother · journal article · DOI 10.1586/14737175.2016.1158102Pimavanserin: An Inverse Agonist Antipsychotic Drug.
Howland RH.
J Psychosoc Nurs Ment Health Serv · journal article · DOI 10.3928/02793695-20160523-01Pimavanserin (Nuplazid) for Parkinson's disease psychosis.
Författaruppgift saknas
Med Lett Drugs Ther · journal articlePimavanserin approved for Parkinson's-related hallucinations, delusions.
Traynor K.
Am J Health Syst Pharm · news · DOI 10.2146/news160037Effects of 7-day repeated treatment with the 5-HT2A inverse agonist/antagonist pimavanserin on methamphetamine vs. food choice in male rhesus monkeys.
Banks ML.
Drug Alcohol Depend · comparative study; research-article; journal article · DOI 10.1016/j.drugalcdep.2016.05.014Pimavanserin.
Hunter NS, Anderson KC, Cox A.
Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2015.51.11.2404001(11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand.
Andersen VL, Hansen HD, Herth MM, Dyssegaard A, Knudsen GM, Kristensen JL.
Bioorg Med Chem Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bmcl.2015.01.017On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H.
Neurochem Res · review-article; review; journal article · DOI 10.1007/s11064-014-1293-3Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.
Meltzer HY, Roth BL.
J Clin Invest · review-article; review; journal article; research support, n.i.h., extramural · DOI 10.1172/jci70678Parkinson disease: Pimavanserin could be useful for treating psychosis in Parkinson disease.
Kingwell K.
Nat Rev Neurol · comment; journal article · DOI 10.1038/nrneurol.2013.233Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C.
Lancet · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(13)62106-6Pimavanserin as treatment for Parkinson's disease psychosis.
Fox SH.
Lancet · comment; journal article · DOI 10.1016/s0140-6736(13)62157-1Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
Hubbard D, Hacksell U, McFarland K.
Behav Pharmacol · comparative study; journal article · DOI 10.1097/fbp.0b013e3283656db6Pimavanserin for the treatment of Parkinson's disease psychosis.
Friedman JH.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2013.819345Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, Hacksell U.
Schizophr Res · comparative study; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.schres.2012.07.029Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.
Price DL, Bonhaus DW, McFarland K.
Behav Pharmacol · journal article · DOI 10.1097/fbp.0b013e3283566082Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
McFarland K, Price DL, Bonhaus DW.
Behav Pharmacol · journal article · DOI 10.1097/fbp.0b013e32834aff98Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers.
Ancoli-Israel S, Vanover KE, Weiner DM, Davis RE, van Kammen DP.
Sleep Med · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1016/j.sleep.2010.10.004Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH.
Neuropsychopharmacology · clinical trial, phase ii; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1038/npp.2009.176Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.
Snigdha S, Horiguchi M, Huang M, Li Z, Shahid M, Neill JC, Meltzer HY.
J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.109.156349Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.
Abbas A, Roth BL.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656560802532707Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE.
J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.105.097006